# Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy

> **NCT02819557** · PHASE2 · COMPLETED · sponsor: **PTC Therapeutics** · enrollment: 14 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Ataluren

## Key facts

- **NCT ID:** NCT02819557
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-09
- **Primary completion:** 2018-02-09
- **Final completion:** 2018-02-09
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2020-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02819557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02819557, "Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02819557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*